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Abstract
Background: There is a need to improve vaccination against respiratory pathogens in calves by stimulation of local
immunity at the site of pathogen entry at an early stage in life. Ideally such a vaccine preparation would not be
inhibited by the maternally derived antibodies. Additionally, localized immune response at the site of infection is
also crucial to control infection at the site of entry of virus. The present study investigated the response to an
intranasal bovine parainfluenza 3 virus (BPI3V) antigen preparation encapsulated in PLGA (poly dl-lactic-co-glycolide)
nanoparticles in the presence of pre-existing anti-BPI3V antibodies in young calves and comparing it to a
commercially available BPI3V respiratory vaccine.
Results: There was a significant (P < 0.05) increase in BPI3V-specific IgA in the nasal mucus of the BPI3V
nanoparticle vaccine group alone. Following administration of the nanoparticle vaccine an early immune response
was induced that continued to grow until the end of study and was not observed in the other treatment groups.
Virus specific serum IgG response to both the nanoparticle vaccine and commercial live attenuated vaccine showed
a significant (P < 0.05) rise over the period of study. However, the cell mediated immune response observed didn’t
show any significant rise in any of the treatment groups.
Conclusion: Calves administered the intranasal nanoparticle vaccine induced significantly greater mucosal IgA
responses, compared to the other treatment groups. This suggests an enhanced, sustained mucosal-based
immunological response to the BPI3V nanoparticle vaccine in the face of pre-existing antibodies to BPI3V, which are
encouraging and potentially useful characteristics of a candidate vaccine. However, ability of nanoparticle vaccine in
eliciting cell mediated immune response needs further investigation. More sustained local mucosal immunity
induced by nanoparticle vaccine has obvious potential if it translates into enhanced protective immunity in the face
of virus outbreak.
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Background
BPI3V is commonly involved as a pathogen related to
bovine respiratory disease (BRD) in cattle and preventing
bovine parainfluenza 3 virus (BPI3V) infection in calves
is challenging [1]. An ideal vaccine for the prevention of
BRD should limit viral infection to the upper respiratory
tract (URT), and prevent its spread to the lungs [2].
However, significant obstacles to effective vaccine design
in neonates is observed due to the fact that young calves
typically have circulating maternally-derived antibodies
and their immune system is relatively immature. Pas-
sively derived maternal antibodies can interfere with and
inhibit the immune response to a vaccine in calves until
their decline by 6 months of age [3]. In early neonatal
life the calf ’s immune system is skewed towards a Th2
type immune response as a consequence of high levels
of progesterone and Th2 cytokines produced at the
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maternal-foetal interface [4–6]. One way of reducing the
effects of maternally derived antibody on vaccine
response is to deliver the vaccine directly onto the nasal
mucosa [7], a route which favour the use of nanoparti-
cles (NPs) [8].
To date, no research has been published examining
the immune response of cattle to PLGA-NPs encapsu-
lating BPI3V antigens. However, there are studies
investigating immune response to PLGA-NPs in ro-
dents [8]. The aim of the present study was to investi-
gate and compare the humoral and cellular immune
responses of artificially reared dairy calves to intrana-
sal immunisation with BPI3V vaccines, Poly (dl-lactic
co glycolide) nanoparticles encapsulating BPI3V nanopar-
ticles (PLGA-BPI3V-NPs), and a commercially available
temperature-sensitive modified live BPI3V vaccine. The
dairy calves used in this study were sero-positive to BPI3V
at the beginning of the study. Our hypothesis was to test if
PLGA-BPI3V-NPs could induce or enhance BPI3V specific
antibodies in calves with pre-existing antibodies and how
this immune response would compare with that induced by
a commercially available intranasal vaccine.
Results
Nanoparticle size, zeta potential and protein loading
efficiency
Nanoparticles encapsulating BPI3V proteins calves with
pre-existing antibodies and were spherical in shape and
uniformly distributed. Particles were on average
225.4 nm in diameter and held a zeta potential of
−22.7 mV (Table 1) with negative polarity. The encapsu-
lation/loading efficiency of BPI3V proteins was 52.6 %,
2.1 mg of 4 mg used for encapsulation.
Clinical assessment of calves
No clinical signs of disease were reported in calves in
any of the treatment groups. Moreover, no adverse reac-
tion to commercial or NP preparation was observed dur-
ing the study Pre-existing levels of antibodies in the
calves and antibody levels are shown in Tables 2 and 3.
Mucus IgA response
Mucus IgA levels in samples collected pre-immunisation
were used as a covariate were not significantly different
(P > 0.05) between the four treatment groups (Fig. 1,
Table 2). There was a significant (P < 0.05) increase in
virus-specific IgA in the nasal mucus of the group 4
calves given the PLGA-BP13V-NPs over the study period
(Fig. 1, Table 2). This IgA response increased gradually
and significantly (P < 0.05) following the ‘booster’ treat-
ment, and continued to rise showing significant (P <
0.05) variation from the other three groups. These
higher mucus IgA levels persisted until study completion
(P < 0.05) at 92 days. Treatment with the commercial
temperature-sensitive modified live virus vaccine (group
1) or the solubilised BPI3V (group 3), did not induce a
statistically significant increase in mucus IgA over the
study period to the end of the experiment. As expected
the group 2 negative controls did not demonstrate any
significant change in IgA levels over the study period.
Serum-IgG-response
Serum IgG levels in samples collected pre-immunisation
were similar (P > 0.05) between the four groups (Fig. 2).
There was a significant increase in serum IgG concen-
tration in groups (1, 3 and 4) relative to the negative
controls group 2 (P < 0.05) (Fig. 2, Table 3) over the
study period. The IgG response to PLGA-BPI3V-NPs
(group 4) increased (P < 0.05) at 1 week post immunisa-
tion and increased gradually after the booster treatment
and continued to rise showing a significant variation
from the negative controls. Calves given the commercial
vaccine (group 1) showed a significant rise (P ≤ 0.05) in
IgG levels that continued to rise after the booster dose
was administered. Calves in group 3 given solubilised
BPI3V proteins demonstrated a significant (P < 0.05) rise
in serum IgG levels from 3 weeks post booster onwards.
There was a positive correlation (P < 0.001) between
mucus IgA and serum IgG responses in all groups.
Interferon (IFN)-γ response
There was no significant change (P > 0.05) in the release
of IFN-γ from peripheral blood mononuclear cells
(PBMC’s) in the four treatment groups over the duration
of the study (data not shown).
Discussion
The present study investigated the humoral and cellular
immune responses of dairy calves (with pre-existing
antibody responses to BPI3V) inoculated with a PLGA-
BPI3V-NP vaccine and a commercial, temperature-
sensitive modified live BPI3V vaccine. The calves given
the PLGA-BPI3V-NPs had significantly greater mucus
IgA responses, compared to the calves in the other
three treatment groups following the booster treatment.
Table 1 Details of the size and zeta potential of NPs
encapsulating BPI3V
PEAKS
Diameter (nm) Vol % Width
225.4 100 190.3
ZETA POTENTIAL
Mobility (u/S/V/cm) −1.7800
Zeta Potential (mv) −22.7800
Charge (fC) −0.03650
Conductivity (uS/cm) 11
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Table 2 Effect of four different intranasal treatments on the nasal mucus IgA immune response (OD values ± s.d) in Friesian calves
Treatments Pre I 1 week PI 2 weeks PI 3 weeks PI 4 weeks PI 1 week PB 2 weeks PB 3 weeks PB 4 weeks PB Half euthanised 5 days PE 2 weeks PE 3 weeks PE T × S
Day 0 Day 7 Day 14 Day 21 Day 28 Day 42 Day 49 Day 56 Day 63 Day 71 Day 76 Day 85 Day 92
Commercial
vaccine
1.28a ± 0.24 1.71a ± 0.79 1.43a ± 0.78 1.72a ± 0.84 1.38a ± 0.54 1.49a ± 0.51 2.33b ± 1.13 1.62a ± 0.71 2.03b ± 0.48 1.7a ± 0.67 1.49a ± 0.52 1.55a ± 0.89 1.71a ± 1 NS
Empty NPs 1.32a ± 0.31 1.59a ± 0.64 1.45a ± 0.45 1.64a ± 0.7 1.22a ± 0.57 1.50a ± 0.57 1.70a ± 0.9 1.32a ± 0.54 1.40a ± 0.77 1.71a ± 0.77 1.21a ± 0.86 0.98b ± 0.61 1.18ab ± 0.78 NS
BPI3V 1.09a ± 0.21 1.96b ± 0.58 1.91b ± 0.72 2.34b ± 0.62 1.92b ± 0.62 2.24b ± 0.61 2.24b ± 0.92 2.21b ± 0.44 2.22b ± 0.76 2.18b ± 0.6 1.36ab ± 0.4 1.49b ± 0.93 1.18a ± 0.87 NS
PLGA-BPI3V-NPs 1.10a ± 0.3 1.73b ± 0.4 1.34ab ± 0.3 1.68b ± 0.44 1.77b ± 0.44 1.85b ± 0.5 2.96c ± 0.66 2.63c ± 0.44 2.94c ± 0.71 3.10c ± 1.28 3.10c ± 0.73 3.15c ± 0.72 3.15c ± 0.71 **
Pre I Pre immunisation sampling, PI Post immunisation, PB Post booster, PE Post euthanasia, T × S treatment × sampling time interaction. Levels of significance: NS = P > 0.05, ** = P < 0.05, *** = P < 0.001. a,b,c, Within a
row, means without a common superscript letter differ (P ≤ 0.05)
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Table 3 Effect of four different intranasal treatments on the serum IgG immune response (OD values ± s.d) values in Friesian calves
Treatments Pre I 1 week PI 2 weeks PI 3 weeks PI 4 weeks PI 1 week PB 2 weeks PB 3 weeks PB 4 weeks PB Half euthanised 5 days PE 12 days PE 2 weeks PE 3 weeks PE T × S
Day 0 Day 7 Day 14 Day 21 Day 28 Day 42 Day 49 Day 56 Day 63 Day 71 Day 76 Day 83 Day 85 Day 92
Commercial
vaccine
0.50a ± 0.39 0.59a ± 0.67 1.01b ± 0.43 0.92b ± 0.45 0.82ab ± 0.45 0.76a ± 0.45 0.94b ± 0.39 1.04b ± 0.42 1.39c ± 0.46 1.47c ± 0.57 1.28c ± 0.48 1.25bc ± 0.56 1.34c ± 0.63 1.25bc ± 0.66 **
Empty NPs 0.47a ± 0.14 0.49a ± 0.19 0.45a ± 0.17 0.45a ± 0.18 0.39a ± 0.15 0.35a ± 0.13 0.40a ± 0.15 0.46a ± 0.21 0.68a ± 0.2 0.66ab ± 0.2 0.72b ± 0.27 0.54ab ± 0.23 0.55ab ± 0.25 0.51ab ± 0.18 NS
BPI3V 0.46a ± 0.16 0.69a ± 0.26 0.72a ± 0.31 0.65a ± 0.23 0.64a ± 0.24 0.69a ± 0.22 0.81a ± 0.26 1.10b ± 0.52 1.10b ± 0.46 1.22bc ± 0.27 1.03b ± 0.33 1.43c ± 0.27 1.14b ± 0.52 1.03b ± 0.47 **
PLGA-BPI3V-NPs 0.43a ± 0.12 0.78b ± 0.44 0.75b ± 0.45 0.69b ± 0.4 0.62b ± 0.33 0.72b ± 0.47 0.77b ± 0.47 0.96bc ± 0.44 0.92bc ± 0.38 1.06c ± 0.42 1.14c ± 0.36 1.11c ± 0.43 1.04c ± 0.46 1.13c ± 0.54 **
Pre I Pre immunisation sampling, PI Post immunisation, PB Post booster, PE Post euthanasia, T × S treatment × sampling time interaction. Levels of significance: NS = P > 0.05, ** = P < 0.05, *** = P < 0.001. a,b,c, Within a
row, means without a common superscript letter differ (P ≤ 0.05)
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This finding suggests an enhanced, more sustained
mucosal-based immunological response to the candi-
date NP vaccine in the face of pre-existing systemic
BPI3V-specific IgG and mucosal IgA. It is also estab-
lished that surface charge or zeta potential is a critical
parameter in controlling the development of stable and
more functional nanoparticles. It is shown that nega-
tively charged surface nanoparticles minimise nonspe-
cific cellular uptake resulting in greater localised
specific response [9]. Nanoparticles with negative zeta
potential used in the current study could possibly be
involved in greater localised BPI3V specific mucosal
IgA response. The mucosal IgA response to PLGA-
BPI3V-NPs observed in the current study is specific to
heat inactivated purified whole BPI3V virus. However,
in the future it would be worth investigating the muco-
sal IgA immune response towards more purified and
concentrated immunodominant BPI3V antigens encap-
sulated in NPs along with assessing IgA response in
combination with mucosal adjuvants.
Fig. 1 Mucosal IgA response to treatments; Figure showing mean (± s.d) mucosal IgA response (OD values) to four intranasal treatments:
Commercial temperature-sensitive modified live virus intranasal vaccine; Empty - negative control (empty NPs); BPI3V -positive control (purified
solubilised BPI3V proteins); and PLGA-BPI3V – NPs vaccine under test. Pre I = Pre immunisation sampling, PI = Post immunisation, PB = Post
booster, PE = Post euthanasia (n = 3 left)
Fig. 2 Serum IgG response to treatments; Figure showing mean (± s.d) serum IgG response (OD values) to four intranasal treatments: Commercial
temperature-sensitive modified live virus intranasal vaccine; Empty - negative control (empty NPs); BPI3V -positive control (purified solubilised
BPI3V proteins); and PLGA-BPI3V – NPs vaccine under test. Pre I = Pre immunisation sampling, PI = Post immunisation, PB = Post booster, PE = Post
euthanasia (n = 3 left)
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The serum IgG responses in the PLGA-BPI3V-NPs
treated calves were largely similar to those in the ani-
mals given the commercial vaccine, although they were
lower between 4 and 5 weeks post-boosting. This could
possibly be explained by the difference in the antigen
release profiles from NPs as described by Kavanagh et al.
[10] and the non-replicating format of the BPI3V NPs.
The pre-existing BPI3V specific IgA and IgG anti-
bodies in these animals were measured before the start
of the study and the levels were largely similar in each
of the treatment groups.
Given that the production of antibody at mucosal
surfaces tends to be transient [7], the sustained pres-
ence of IgA in mucus on the URT surfaces of the calves
given the PLGA-BPI3V-NPs suggests viral antigen pre-
sented in this form can result in a more sustained
release of antigen over a longer period of time. Mucosal
immunisation has become an important strategy in
vaccine design as this approach stimulates both muco-
sal and systemic immune responses whereas parenteral
immunisation typically results in only a systemic
response [11]. Mucosal protection is particularly rele-
vant in the context of respiratory pathogens where their
major portal of entry is frequently the nasal mucosa
[12, 13]. Mucosa-associated lymphoid tissue (MALT),
an essential part of the mucosal immune system is the
initial inductive site for nasal mucosal immunity. Anti-
gens are sampled from mucosal surfaces and naïve B-
and T-lymphocytes are stimulated. MALT structures
(lymphoid follicles and T cell-dependent interfollicular
areas) are the origin of lymphocyte migration to muco-
sal effector sites. Lymphatics transport immune cells
and antigens to regional lymph nodes that are induct-
ive sites of mucosa and augment the immune re-
sponses [14].
Sustained release of soluble antigen, as is likely to
occur from NPs, has been shown to induce more ro-
bust immune responses than a larger single ‘spike’ or
bolus of antigen given parenterally [15, 16]. In terms
of potentially further enhancing the immunological
impact of our candidate nanoparticle vaccine, muco-
adhesive agents and immune potentiators/modulators such
as chitosan, CpG motifs and MPLA could be used [17–21].
Muco-adhesive agents like chitosan has been shown to
increase the penetration potential of the particles by
increasing their adherence to mucosal membrane resulting
in opening of tight junctions in the nasal mucosa.
No significant differences were detected in the
concentrations of both nasal IgA and serum IgG spe-
cific BPI3V antibodies in any of the calves prior to
study commencement and these Ig profiles are typical
of commercially sourced colostrum-fed dairy calves
[22, 23]. While these pre-existing antibodies may well
have been maternally derived, the fact that the calves
were not sampled until between 4 and 5 months of age
means the possibility of prior exposure to BPI3V cannot be
ruled out. However, there was no recent history of clinical re-
spiratory disease on the farm where the calves were sourced.
The failure of the commercial vaccine to induce an
anamnestic IgA and IgG antibody response instantly
within a week of booster administration could possibly
reflect the inhibitory effects of the circulating pre-
existing antibodies as described previously [4, 24–27]
which resulted in complete vaccine failure after a sin-
gle dose and started to show some response after the
second dose. Vangeel et al. [23] demonstrated that a
single dose BPI3V vaccine did not provoke a signifi-
cant rise in serum antibody levels in the presence of
maternal antibodies and Greenberg et al. [26] reported
that multiple doses of BPI3V vaccine were required to
elicit protective immunity. Calves given the commer-
cial live vaccine demonstrated significant systemic IgG
responses 4–5 weeks after boosting. Such a finding
has previously been reported in vaccine studies in
cattle where efficacy of intranasal and intramuscular
live attenuated respiratory vaccines was investigated
[23, 26, 28, 29].
The smaller systemic IgG response in the PLGA-BPI3V-
NPs treated animals relative to the commercial vaccine-
treated calves was perhaps not surprising given the likely
reduced quantity of inactive virus antigen in the NPs,
relative to the ability of the live attenuated virus to repli-
cate and therefore generate large quantities of antigen. In
terms of pre-existing antibody interfering with vaccin-
ation, it is possible that pre-existing mucosal IgA
could also negatively impact on conventional or NPs
vaccines delivered onto mucocal surfaces. However as
the NPs encapsulate the antigen it may be more likely
that there would be less interference of existing anti-
bodies on the development of an immune response to-
wards vaccine NPs delivered by the aerosol route.
T-cells recognise antigenic peptides presented on
MHC-encoded molecules and are fundamental to
CMI. MHC-II-restricted T-cells (CD4) are known to
have a primary role in the production of macrophage
activating cytokines such as IFN-γ. IFN-γ enhances
the ability of infected cells and phagocytes to inhibit
the activity of infecting organisms. Interferon-γ can
also be non-specifically produced by gamma-delta T
and natural killer cells [30]. While some animals
appeared to show IFN-γ responses at few occasions
there were no consistent significant patterns correlat-
ing with vaccination. The antigen prepared for IFN-γ
stimulation was a crude purified virus preparation and
there could be other cellular antigens that may have
caused some stimulation of cells to produce IFN-γ.
Interestingly, enhanced mucosal IgA secretion has previ-
ously been linked to local IFN-γ production, where T cell
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products such as IFN-γ enhanced the translocation of
large amounts of locally produced IgA through epithelial
cells into mucosal secretions [31, 32].
Conclusion
In conclusion, calves administered intranasal PLGA-
BPI3V-NPs had significantly greater mucus IgA re-
sponses, compared to calves in the other three treat-
ment groups. The increase in mucosal IgA response to
NPs demonstrate the potential of vaccine delivery
system that facilitates the slow release of antigen from
the protective coating of PLGA NPs in the nasal mu-
cosa. Of primary importance is that the antigen is
protected from the deteriorative effects of mucosal en-
zymes and, being in the nano size range, has the
potential to cross the mucosal barrier. Neutralizing
respiratory viruses at the site of entry by eliciting local
IgA response is crucial in young claves with a develop-
ing immune system which are subjected to an inten-
sive milk management feeding system. Current study
findings suggest an enhanced, sustained mucosal-based
immunological response to the BPI3V nanoparticle
vaccine in the face of pre-existing systemic IgG, which
are encouraging and potentially useful characteristics of
a candidate vaccine. This more sustained local mucosal
immunity induced by the candidate PLGA-BPI3V-NPs
vaccine has obvious potential if it translates into enhanced
protective immunity in the face of virus outbreak.
Methods
Growth of BPI3V virus pools
A BPI3V isolate (2005/015033-Lung A), recovered from
the pneumonic lung tissue of a 10 day old calf that was
subject to post-mortem examination at the Agri-Food &
Biosciences Institute (AFBI) in December 2005, was used
to provide the necessary pools of virus. Canted, 75 cm2
neck flasks monolayered with foetal calf lung (FCL) cells
of between 18 and 22 passages were obtained from the
Cell Culture Laboratory at AFBI. Once a satisfactory
monolayer of cells was visible upon microscopic examin-
ation, the cell maintenance medium was poured off and
the flasks were infected with 2 ml of 1:300 diluted BPI3V
working pool 1 (107.8 tissue culture infectious dose 50
(TCID50)/ml) and incubated at 37 °C in 5 % CO2 for 1 h.
Then, 18 ml of maintenance medium [Eagle’s BHK, 2 %
heat inactivated foetal bovine serum, gentamicin (0.1 %)
and glutamine (1 %)] was added to each flask and the
inoculated monolayers incubated at 37 °C in 5 % CO2
for 7 days. The flasks were examined daily over 7 days
for evidence of cytopathic effect (CPE).
Harvesting of BPI3V
Following the 7 day incubation, extreme viral CPE
(90 %) was evident and the flasks were transferred to a
−80 °C freezer for 1 h. The flasks (16) were then thawed
at 37 °C in a hot water bath and this freeze/thaw proced-
ure was repeated three times. Cells were removed from
the base of the flasks using a cell scrapper, pooled and
placed in 400 ml glass bottles and stored at −80 °C prior
to the virus purification step.
BPI3V purification
An aliquot (320 ml) of the frozen virus pool (107.8
TCID50/ml) was defrosted at 37 °C in a water bath.
The thawed virus pool was dispensed into smaller bot-
tles (80 ml in 100 ml bottles), chilled over ice, and
sonicated (Sonics, Vibracell, USA) at full power for
1 min to disrupt any virus clumps before re-pooling
into one glass bottle. The re-pooled virus suspension
was heated in a water bath at 37 °C for 15 min and
divided equally into polycarbonate centrifuge tubes
(Corning, Mexico) each of which were spun down for
20 min at 1500 × g. The supernatant was decanted,
leaving the cell pellet. The supernatant was then
divided equally into polycarbonate tubes and balanced
with 0.01 M PBS for ultracentrifugation (93,000 × g for
4 h at 4 °C). The virus pellets were re-suspended in
2 ml of PBS. The mixture was sonicated to create a
suspension and the concentrated virus preparation
was stored at −80 °C until required.
Nanoparticle production
Purified BPI3V suspended in 2 ml of 0.01 M PBS was
defrosted at room temperature. The virus suspension
was heated at 70 °C for 10 min in a water bath for virus
inactivation. Before encapsulating the viral proteins
inside PLGA, gel electrophoresis was performed to
assess the quality of the BPI3V proteins. Additionally,
total protein mass in the virus suspension was calculated
using the bicinchoninic acid (BCA) protein assay kit
(Pierce, Thermo scientific, USA). For NP preparation,
1 ml of viral proteins (4 mg/ml) was emulsified with
300 mg of PLGA polymer dissolved in 8 ml of dichloro-
methane (DCM) (Sigma), 2 ml of acetone and 6 %
Synperonic PE/F68 (FLUKA analytical, UK) using high-
speed sonication at 55 % power for 2 min over ice. The
emulsion was sonicated with 100 ml of 2.5 % emulsion
stabiliser, polyvinyl alcohol (PVA) (Sigma) (2.5 g/100 ml
distilled water) at 55 % power for 10 min over ice to
form the final w/o/w solution [33, 34]. This final solu-
tion was left stirring overnight at room temperature in
a fume hood followed by ultra-centrifugation (Thermo
scientific Sorvall WX ultra series centrifuge, WX ultra
80) at 93,000 × g for 30 min at 4 °C. The pellets of NPs
were washed three times by ultracentrifugation with
distilled water (dH2O) and sonicated at full power (55 %) to
obtain a uniform suspension before measuring the size and
zeta potential of the NPs using Zetatrac (Microtrac, USA)
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equipment. The suspension was then freeze dried in a
(Thermo ModulyoD) freeze drier under the conditions
(pre-frozen sloped at −70 °C, placed in condenser chamber
for 48 h keeping the temperature of condenser at −50 °C
and pressure of chamber below 70 microbars). After freeze
drying vials were sealed at 4 °C until required.
Size and zeta potential measurement
The size and zeta potential (the charge residing on or
near the surface of a suspended particle) of the NPs was
measured using Zetatrac (Microtrac, USA). Zetatrac uses
dynamic light scattering concept with high frequency
electric field excitation and the interaction of random
Brownian with driven electric field motion of particle
suspensions to measure the size and zeta potential
across the particles. A total of 3 ml of NP suspension in
distilled H2O at the appropriate concentration and load-
ing index was added to the measurement chamber of
the Zetatrac instrument.
Efficiency of encapsulation process
The content of encapsulated proteins in the NPs was
determined using a bicinchoninic acid (BCA) protein
assay kit (Pierce, Thermo scientific, USA). Approxi-
mately 10 mg of NPs were dissolved in 600 μl 0.1 M
NaOH containing 5 % sodium dodecyl sulphate (BDH).
The extraction was stopped after 4 h at 37 °C by adding
500 μl 0.1 M HCl. The solution was centrifuged to
separate the proteins from the NPs. The supernatant
was decanted and stored at −20 °C until analysed. The
protein content was determined using a BCA protein assay
kit [35–37] and a standard curve of known concentrations
of bovine serum albumin (BSA) (25–2000 μg/ml) in an
equal solution of 0.1 M NaOH containing 5 % SDS (sodium
dodecyl sulfate) and 0.1 M HCl. The BCA working reagent
was prepared by combining 50 parts of BCA stock solution
and 1 part of 4 % cupric sulphate. Twenty five microlitres
of each standard and supernatant from the NPs extrac-
tion procedure was added in duplicate to a 96-well
plate (Sterilin, UK). Two hundred microlitres of work-
ing BCA solution was then added into each well. The
microtitre plate was covered with a plate sealer and
incubated for 30 min at 37 °C with gentle shaking. After
30 min of incubation, the plate was cooled to room
temperature and the absorbance of water-soluble pur-
ple product was measured at 562 nm using a micro-
plate reader (Tecan Sunrise, Switzerland).
Antibody detection
IgA ELISA
Bovine parainfluenza virus type 3-specific IgA in nasal
washings was detected by ELISA. Ninety-six-well ELISA
plates (Immulon 1B, Dynex Technologies) were coated
overnight with purified BPI3V as described above by
adding 100 μl per well of a solution of 1 μl/4 ml of puri-
fied BPI3V in 0.05 M sodium carbonate–bicarbonate
buffer (pH 9.6) at 4 °C. After 24 h, the plates were
washed three times with wash solution containing Tris
(6 g/l), NaCl (8.19 g/l) and 0.05 % Tween 20. A total of
200 μl of wash solution containing Tris, NaCl and
Tween was then added to the wells and incubated for
30 min at 37 °C. The plates were washed three times
with wash solution. The nasal mucus samples were di-
luted 1:4 in conjugate diluent (Bethyl Laboratories, Inc.,
USA) of same composition as of wash solution contain-
ing 0.05 % Tween 20 and 100 μl of each sample was
added in duplicate to the wells of the coated plates. The
plates were incubated for 1 h at 37 °C. The plates were
then washed five times with wash solution. One hundred
microlitres of rabbit anti-bovine IgA horseradish perox-
idase (HRP) conjugate (Bethyl Laboratories, Inc. USA),
diluted 1:10,000 in conjugate diluent containing 4 %
horse serum (to prevent non-specific binding) was added
to each well and the plates were again incubated for 1 h
at 37 °C followed by washing as previously described.
One hundred microlitres of the enzyme substrate (TMB)
(Bethyl Laboratories, Inc. USA) were added to each well,
followed by a 15 min incubation at room temperature in
the dark with colour development terminated by adding
100 μl of 0.18 M hydrosulphuric acid (H2SO4). Optical
density (OD) values were read at 450 nm using an
ELISA reader (Tecan Sunrise, Switzerland).
IgG ELISA
A BPI3V antibody ELISA kit (Svanovir, Scandinavia) was
used to analyze serum IgG. Briefly, serum samples were
diluted 1/25 in PBS-Tween buffer and applied to the
wells for 1 h at 37 °C, before washing three times with
PBS-Tween and applying anti-bovine IgG conjugate
(provided in the kit) for 1 h. The substrate and ‘stop’ so-
lution used were also supplied with the ELISA kit. Ab-
sorbance was read at 450 nm using an ELISA reader
(Tecan Sunrise, Switzerland).
Stimulated lymphocyte production of interferon-γ (IFN-γ)
The stimulated lymphocyte production of IFN-γ was de-
termined from harvested supernatant following a whole-
blood culture [38]. Heparinised blood samples (10 ml)
were collected from animals and cultured in sterile 96-
well flat culture plates (200 μl whole blood/well). For
non-stimulated controls, 25 μl of PBS was added to wells
and for antigen-specific stimulation, a total of 25 μl of
BPI3V antigen in PBS was added (final antigen concentra-
tion of 4 μg/ml). As a positive control, pokeweed mitogen
(PWM) was added (final concentration 4 μg/ml). Control
or stimulated wells were established in duplicate and the
cell culture was incubated for 24 h at 37 °C in an atmos-
phere of 5 % CO2 in air. Aseptic techniques were
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practiced during this procedure. The culture plates were
then centrifuged at 1,700 × g, at 8 °C for 20 min; the
supernatant was harvested and stored frozen at −20 °C
until assayed. The supernatant was assayed using the
BOVIGAM® gamma interferon ELISA for cattle according
to the manufacturer’s guidelines (Prionics, Switzerland).
The IFN-γ response was determined by comparing the net
OD for each sample.
Experimental animals
Twenty four weaned Friesian bull calves were commer-
cially sourced at day 0 (mean age 141 [s.d, 8.8 days] at
day 0, mean weight 121.8 [s.d, 21.4] kg). Calves were
identified by individual ear tag number and housed in
open-fronted straw-bedded sheds. The calves were
weighed seven days before the immunisation procedure.
Water was provided ad libitum. Calves were fed high
quality haylage ad libitum and 1.5 kg per/head/ day of
16 % calf rearing ration. Calves were immunised 83 [s.d,
7.15] days after weaning (day 0).
Experimental treatments
All calves were blood and nasal mucus sampled on day 0,
to determine the presence of BPI3V specific pre-existing
IgG and IgA in serum and mucus, respectively. There was
no history of respiratory outbreaks on the farm from where
the calves came and the vaccines had no history of vaccin-
ation for BRD. The calves were clinically examined and
declared fit for the study on day 0 by the Named Veterinary
Surgeon and were randomly assigned based on live-weight
to one of the following four treatment groups with six
calves in each treatment group.
1) Commercial intranasal vaccine group – given
temperature-sensitive, modified live virus vaccine
(Rispoval RS + PI3 intranasal, Pfizer) was given
according to manufacture instructions i.e. 1 ml in
each nostril and boosted at day 35.
2) Negative control group – given empty PLGA-NPs.
3) Positive control group – given purified BPI3V
proteins (1.3 mg of BPI3V protein/2 ml of PBS
4) PLGA-BPI3V-NPs (1.3 mg/2 ml of PBS).
Fifteen minutes prior to immunisation of the calves on
day 0, the freeze dried NPs were suspended in 0.01 M PBS
and mixed thoroughly for 1 min by vortexing. Briefly, 1 ml
of each suspension was inoculated into each nostril of each
calf using an intranasal spray applicator (Pfizer). The total
volume administered was 2 ml/calf. Calves were restrained
in a crush with the head held in an upright position, nos-
trils facing upwards for 30 s after each inoculation. Blood
was collected from the jugular vein and nasal mucus from
the nostrils weekly over the next 4 weeks (Table 4). Mucus
was collected using nasal sponges inserted into each nostril
for 1 min and then squeezed out using a sterile syringe into
a 5 ml sterile collection tube. Nasal mucus was centrifuged
to remove particulate debris. Nasal mucus and serum were
screened for mucosal IgA and serum IgG concentrations,
respectively using ELISA as mentioned in section 5.7.1
and 5.7.2.
Whole blood samples were collected and stimulated as
described above for the production of IFN-γ. Calves
were administered a booster immunisation in the same
manner as the first immunisation dose on day 35 includ-
ing commercial vaccine and the same parameters were
measured weekly for a further 5 weeks (Table 4). Half of
the calves from each group were necropsied on day 76.
Blood and nasal mucus from remaining calves was
collected for the following 3 weeks (Table 4) to determine
the levels of serum IgG, mucus IgA and IFN-γ production.
Statistical analysis
Genstat statistical software was used to analyse the data.
Repeated measure ANOVA was used to analyse differ-
ences among treatments at individual bleeds and over
the study period. Pre-immunisation blood and nasal
mucus were used as covariates in the analysis, and
Table 4 Timeline showing timings of blood and nasal sample
collection from calves
Intranasal treatments
(6 animals/group)
Commercial Vaccine Empty NPs BPI3V
proteins
PLGA-
BPI3V-NPs
Blood collection Nasal mucus collection
Day 0 (Immunisation) Day 0 (Immunisation)
Day 7 (1 week PI) Day 7
(1 week PI)
Day 14 (2 weeks PI) Day 14
(2 weeks PI)
Day 21 (3 weeks PI) Day 21
(3 weeks PI)
Day 28 (4 weeks PI) Day 28 (4 weeks PI)
Day 35
(Booster inoculation)
Day 35
(Booster inoculation)
Day 42 (1 week PB) Day 42 (1 week PB)
Day 49 (2 weeks PB) Day 49 (2 weeks PB)
Day 56 (3 weeks PB) Day 56 (3 weeks PB)
Day 63 (4 weeks PB) Day 63 (4 weeks PB)
Day 71
(n = 3, euthanised)
Day 71 (n = 3, euthanised)
Day 76 (5 days PE) Day 76 (5 days PE)
Day 83 (12 days PE)
Day 85 (2 weeks PE) Day 85 (2 weeks PE)
Day 92 (3 weeks PE) Day 92 (3 weeks PE)
PI Post immunisation, PB Post booster, PE Post euthanasia
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P < 0.05 was considered significant. Fisher’s protected
least significant difference test was used to determine
differences among the same and different treatments at
different sampling times. Correlation analysis was per-
formed to determine the relationship between IgG, IgA,
and IFN-γ concentrations.
Animal experimentation ethics
All animal studies were carried out in accordance with
the UK Animals (Scientific Procedures) Act 1986. Ap-
proval was granted by the local AFBI Ethical Review
Committee and a formal project license was approved
by the regulatory authorities.
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